If you've searched for weight regain after stopping GLP-1 medication, you've probably seen headlines that sound like one clear answer. The trials behind them aren't built the same way, though, and the design often shapes the result as much as the drug does. Let's sort out what these studies actually test before we talk about any numbers.
Weight regain after stopping GLP-1 medication depends heavily on how a study was designed. Here is how to read the trials on weight, lean mass, appetite, and maintenance.
Stopping is not one event
Researchers ask different questions depending on how they set up a trial. In a continuous treatment design, people keep taking the drug and are compared with people on placebo. That tells you how the drug works over a longer window. In a withdrawal design, people take the drug for a set period and then stop, which shows what happens after the drug leaves the body. A switch-to-placebo design looks similar, but people are randomized at the switch point, and that randomization is what makes the comparison meaningful. A dose step-down design lowers the dose instead of stopping altogether, asking whether a smaller amount can hold results. Each design answers a different question, so a finding from one shouldn't be read as a finding about another.
The best-known withdrawal data come from two trial programs. STEP 4 tested semaglutide 2.4 mg and was published in JAMA in 2021 by Rubino and colleagues. It used a lead-in period on the drug before participants were randomized to continue semaglutide or switch to placebo. SURMOUNT-4 tested tirzepatide and was published in JAMA in 2024, also using an open-label lead-in before randomization. Before you rely on any detail from these trials, open the primary paper and confirm the name, year, sample size, and follow-up length. Secondary articles often compress or mislabel these facts, and that's where errors tend to creep in.
When a headline says someone 'regained' a certain percentage, three things determine what that actually means. The first is the baseline. Regain measured from the lowest weight reached on treatment looks different from regain measured from the starting weight. The second is the timepoint. A number taken a few weeks after stopping tells a different story than one taken a year later. The third is the comparison group. If the control group kept taking the drug, the gap reflects the withdrawal itself. If everyone stopped, you're looking at a different question. Check those three things first, and the rest of the article gets much easier to read.
